ResMed (RMD) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $226.00 --0%
Financial Fact:
Income taxes (note 13): 16.82M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Income taxes (note 13): 16.82M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q1 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $380.4 million versus the consensus estimate of $375 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
- Lucid Diagnostics Inc. (LUCD) Reports In-Line Q2 EPS
- Healthcare Triangle Reports 322% Increase in Gross Profit and 158% Increase in Revenue for Q2 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
